Literature DB >> 22136052

Bioanalytical aspects of clinical mass balance studies in oncology.

Anne-Charlotte Dubbelman1, Hilde Rosing, Jan H M Schellens, Jos H Beijnen.   

Abstract

Clinical mass balance studies aim to investigate the absorption, distribution, metabolism and excretion (ADME) of a(n) (often radiolabeled) drug, following a single administration to humans. They are perfectly suited to determine the disposition and major metabolic pathways of a drug, the exposure to the parent drug and its metabolites, and the rate and route of elimination. A mass balance study, however, poses interesting challenges to the analysis of parent drug and metabolites in different biological matrices. Using recent clinical mass balance studies in oncology as an example, this review focuses on the aspects of mass balance studies, from bioanalytical assay development, analysis of clinical samples to reporting of study results. Along the way, it discusses bioanalytical problems and practical solutions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22136052     DOI: 10.4155/bio.11.276

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  3 in total

1.  Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.

Authors:  Oliver von Richter; Giorgio Massimini; Holger Scheible; Istvan Udvaros; Andreas Johne
Journal:  Br J Clin Pharmacol       Date:  2016-09-19       Impact factor: 4.335

2.  Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison.

Authors:  Anne-Charlotte Dubbelman; Cynthia M Nijenhuis; Robert S Jansen; Hilde Rosing; Hitoshi Mizuo; Shinki Kawaguchi; David Critchley; Robert Shumaker; Jan H M Schellens; Jos H Beijnen
Journal:  Invest New Drugs       Date:  2016-03-28       Impact factor: 3.850

Review 3.  Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment.

Authors:  Lotte van Andel; Hilde Rosing; Jan Hm Schellens; Jos H Beijnen
Journal:  Mar Drugs       Date:  2018-07-23       Impact factor: 5.118

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.